Vamil Divan, Guggenheim Securities biopharmaceutical analyst, joins 'Power Lunch' to discuss Merck's troubles in China.

Guggenheim maintained a positive outlook on Chewy Inc . (NYSE:CHWY) by increasing its price target to $42.00, up from the previous $36.00, while keeping a Buy rating on the stock. The new target ...

Philanthropists Alfred and Gail Engelberg sold their lakefront Palm Beach home for $23.8 million, a steep discount from its ...

The New York investment manager attracted new backers, including Allianz Global Investors, by allowing them to acquire ...

Levi Strauss & Co. (NYSE:LEVI – Free Report) had its price objective raised by Guggenheim from $20.00 to $22.00 in a research ...

The Guggenheim CEO and LA Dodgers owner committed $100 million to start LA Rises, which he will lead with Magic Johnson and ...

Guggenheim raised the firm’s price target on AutoNation (AN) to $207 from $189 and keeps a Buy rating on the shares. Ahead of ...

Guggenheim Investments today announced that certain closed-end funds have declared their distributions. The table below summarizes the distribution schedule for each closed-end fund (collectively, the ...

Shares of Enphase Energy (ENPH) rose on Friday after Guggenheim, led by five-star analyst Joseph Osha, upgraded its rating from Sell to Neutral ...

Guggenheim Partners' chief investment officer forecast on Monday that the U.S. Federal Reserve is likely to cut interest ...

WALTHAM, Mass. and BOULDER, Colo., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: COGT), a biotechnology company focused on ...

Premiering at Sundance, the film looks at the protests surrounding the hiring of a new president at Gallaudet University in ...